HIGHLIGHTS
- who: Simon J. Crabb et al. from the (UNIVERSITY) have published the research work: A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma, in the Journal: (JOURNAL)
SUMMARY
PURPOSE A DNA repair deficiency (DRD) phenotype exists within a subset of metastatic urothelial carcinomas (mUC) predicting benefit from platinum-based chemotherapy. The authors tested switch maintenance therapy with the poly ADP-ribose polymerase inhibitor rucaparib, following chemotherapy, for DRD biomarker-positive mUC. METHODS DRD biomarker-positive mUC patients . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.